A Phase 2 interventional study of Adebrelimab plus Apatinib and Adebrelimab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, sponsored by Peking University Cancer Hospital & Institute. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-22.
Sponsored by Peking University Cancer Hospital & Institute · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing adebrelimab in Carcinoma, Hepatocellular — 12 open to participants now, 12 under way, 1 of them phase 3. adebrelimab · Carcinoma, Hepatocellular.
Among the 13 studies testing adebrelimab in Carcinoma, Hepatocellular, this one is the 4th largest by planned enrollment, is one of 4 that started in 2024, is one of 8 in phase 2, reaches primary completion later than 7 of the 11 other live ones, and was the 6th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →12 of the 13 studies testing adebrelimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:
Nanjing Tianyinshan Hospital · Sites in China
Ages 18+
Zhejiang Cancer Hospital · Sites in China
Ages 18–75
Qilu Hospital of Shandong University · Sites in China
Ages 18+
Mian XI · Sites in China
Ages 18–75
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 1
First in 2022; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 111 is above the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 52 across the 13 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 10 most frequent:
Peking University Cancer Hospital & Institute is the lead sponsor of 269 studies on the registry; 128 are open to participants now.
10 studies in Carcinoma, Hepatocellular by Peking University Cancer Hospital & Institute: 4 open now, 5 under way, none of them phase 3.
Among the 10 studies in Carcinoma, Hepatocellular by Peking University Cancer Hospital & Institute, this one is the only one that started in 2024, is one of 5 in phase 2, and was the 7th registered.
Peking University Cancer Hospital & Institute’s Carcinoma, Hepatocellular studies by the year they started, since 2015.
3 of the studies testing adebrelimab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06454578Qilu Hospital of Shandong UniversityAdjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection | 2026-12 |
| NCT06360042Peking University Cancer Hospital & InstituteAnti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | 2027-03-31 |
| NCT07192848Song PengAdebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies testing adebrelimab in Carcinoma, Hepatocellular, from their registry updates:
Among Peking University Cancer Hospital & Institute’s 10 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adebrelimab(1200mg iv q3w) plus Apatinib(250mg po qd)
Drug: Adebrelimab plus Apatinib
Adebrelimab(1200mg iv q3w)plus Bevacizumab(15mg/kg iv q3w)
Drug: Adebrelimab plus Bevacizumab
Camrelizumab (200mg iv q2w) plus Apatinib(250mg po qd)
Drug: Camrelizumab plus Apatinib
Drug pages: AdebrelimabStudies of AdebrelimabAdebrelimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ApatinibStudies of ApatinibApatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily
Drug pages: AdebrelimabStudies of AdebrelimabAdebrelimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks
Drug pages: CamrelizumabStudies of CamrelizumabCamrelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ApatinibStudies of ApatinibApatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily
12-month overall survival rate
Time frame: Up to approximately 3 years
ORR
Assessed by the investigator per RECIST v1.1 criteria
Time frame: Up to approximately 3 years
DCR
Assessed by the investigator per RECIST v1.1 criteria
Time frame: Up to approximately 3 years
DoR
Assessed by the investigator per RECIST v1.1 criteria
Time frame: Up to approximately 3 years
TTR
Assessed by the investigator per RECIST v1.1 criteria
Time frame: Up to approximately 3 years
TTP
Assessed by the investigator per RECIST v1.1 criteria
Time frame: Up to approximately 3 years
PFS
Assessed by the investigator per RECIST v1.1 criteria
Time frame: Up to approximately 3 years
OS
Time frame: Up to approximately 3 years
safety according to NCI Common Terminology Criteria for Adverse Events, version 5.0.
Time frame: Up to approximately 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Mar 2027, 38 months after the start.
Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 38 months is below that.
Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adebrelimab · Apatinib · Bevacizumab · Camrelizumab
Peking University Cancer Hospital & Institute →